
Note sull'episodio
This week, we’re chatting with Haseeb Ahmad, CEO of Purespring Therapeutics, about gene therapies in kidney disease, and with Pahini Pandya, Panakeia CEO, about colorectal cancer biomarkers, the potential of AI in clinical decision-making and how AI can transform workflows in diagnostics.
Times:
03:34 Purespring
24:11 Panakeia Technologies
Purespring Therapeutics
Purespring is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function.
The company is focused on transforming the treatment of kidney disease—an area of enormous unmet need, with more than 840m people worldwide living with chronic kidney disease.
Purespring’s lead programme, PS-002, ...
Parole chiave
biotech
biotechnology
cancer
artificial intelligence
biomarkers
kidney disease
Panakeia
Purespring Therapeutics
